The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis

Background. The recommended therapy for patients with chronic hepatitis C (CHC), genotype 1, who have cirrhosis and have failed prior therapy is 12 weeks of sofosbuvir (SOF), ledipasvir (LDV), and ribavirin (RBV). This recommendation is based on expert opinion, and the efficacy of 12 weeks of SOF/LD...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Can J Gastroenterol Hepatol
Hlavní autoři: Stokes, William, Fenton, Carol, Clement, Fiona, James, Matthew, Ronksley, Paul, Tang, Karen L.
Médium: Artigo
Jazyk:Inglês
Vydáno: Hindawi 2017
Témata:
Review Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5358456/
https://ncbi.nlm.nih.gov/pubmed/28367429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/6468309
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky